Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic
Zeitschrift für Gastroenterologie · 01.04.2023 · 61 (04) · 375-380
DOI: 10.1055/a-1821-9009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.04.2023. Verfasst von Claus Niederau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Postfach 10 12 03, Oberhausen, Germany. Hauptthemen laut MEDLINE: Gaucher Disease, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Continuation of standard management of Gaucher disease (GD) has been challenging during the COVID-19 pandemic, resulting in infrequent/missed infusions and follow-up appointments. Little data are available on the consequences of these changes and on the SARS-CoV-2 vaccinations in German GD patients.
Methods
A survey with 22 questions about GD management during the pandemic was sent to 19 German Gaucher centres. It was answered by 11/19 centres caring for 257 GD patients (almost ¾ of the German GD population); 245 patients had type 1 and 12 had type 3 GD; 240 were ≥ 18 years old.
Results
Monitoring intervals were prolonged in 8/11 centres from a median of 9 to 12 months. Enzyme replacement therapy (ERT) was changed to home ERT in 4 patients and substituted by oral substrate reduction therapy (SRT) in 6 patients. From March 2020 to October 2021, no serious complications of GD were documented. Only 4 SARS-CoV-2 infections were reported (1.6%). Two infections were asymptomatic and two mild; all occurred in adult type 1, non-splenectomized patients on ERT. Vaccination rate in adult GD was 79.5% (95.3% mRNA vaccines). Serious vaccination complications were not reported.
Conclusions
The COVID-19 pandemic has lowered the threshold for switching from practice- or hospital-based ERT to home therapy or to SRT. No major GD complication was documented during the pandemic. Infection rate with SARS-CoV-2 in GD may rather be lower than expected, and its severity is mild. Vaccination rates are high in GD patients and vaccination was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Postfach 10 12 03, Oberhausen, Germany.
- Department of Nephrology, Technical University of Munich, School of Medicine, München, Germany.
- Klinik f. Innere Medizin und Geriatrie, AMEOS Klinikum St. Marien, Oberhausen, Germany.
- Endokrinologikum, Hamburg, Germany.
- Medizinische Klinik f. Endokrinologie und Stoffwechselmedizin, Charité Campus Virchow, Berlin, Germany.
- Clinical Science for LSD, SphinCS, Hochheim, Germany.
ORCID-Profile: Stephan Vom Dahl
Zitieren
APA
Niederau, C., Regenbogen, C., Fruehauf, H. M., Merkel, M., Ziagaki, A., Mengel, E., Baerwald, C., Muschol, N., Staufner, C., Lampe, C., Gillessen, A., Koehler, J. P., & Vom Dahl, S. (2023). Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic. Zeitschrift für Gastroenterologie, 61(04), 375-380. https://doi.org/10.1055/a-1821-9009
Vancouver
Niederau C, Regenbogen C, Fruehauf HM, Merkel M, Ziagaki A, Mengel E, et al. Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic. Zeitschrift für Gastroenterologie. 2023;61(04):375-380. doi:10.1055/a-1821-9009
BibTeX
@article{Niederau2023,
author = {Niederau, Claus and Regenbogen, Claudia and Fruehauf, Hans-Martin and Merkel, Martin and Ziagaki, Athanasia and Mengel, Eugen and Baerwald, Christoph and Muschol, Nicole and Staufner, Christian and Lampe, Christina and Gillessen, Anton and Koehler, Jan Philipp and Vom Dahl, Stephan},
title = {Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic},
journal = {Zeitschrift für Gastroenterologie},
year = {2023},
volume = {61},
number = {04},
pages = {375--380},
doi = {10.1055/a-1821-9009}
}
EUVIMED